6 RESULTS
COMMENT When we first saw this paper published, we noted that one of the PCR primers was identical to that published in our primary paper; the other primer had single base deletion. The remaining sequence facilitated their novel method, but that failed to ...
COMMENT The assumptions are that amyloid deposition is the instigating event and thus the right target, that drugs that reduce amyloid accumulation in the brain may be the right drugs, and that performing drug trials in normal people can be safe and reasonable. I ...
COMMENT It is positive that Cruchaga et al. support the association between the poly-T repeat (“523”) and risk of late-onset Alzheimer’s disease (LOAD) that we first reported in 2009. Additionally, this group completed a phylogenetic analysis of the ApoE-Tomm40 ...
COMMENT It is not surprising at all that there is a difference in the "hippocampal atrophy rates and less AD pathology in CSF of ApoE2 carriers (relative to E3/E3 participants) from the ADNI cohort of cognitively normal individuals." The critical ...
COMMENT For mitochondrial effects in AD please see our Pharmacogenomics Journal article published in 2009. localizing a variable polyT mutation in the translocase of the outer mitochondrial membrane as a diagnostic predictor of risk for AD. allen.roses 0 ...
COMMENT Response from Allen Roses et al. to Tanzi Comment Below please find a short, absolute rebuttal to the comments made by Rudy Tanzi. It is followed by a fairly detailed commentary on each point, including copies of relevant dated correspondence that clarify ...
